Skip to main content

Lutetium lu 177 dotatate Disease Interactions

There are 3 disease interactions with lutetium lu 177 dotatate.

Moderate

Lutetium Lu 177 dotatate (applies to lutetium lu 177 dotatate) hepatic dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Lutetium Lu 177 dotatate does not undergo hepatic metabolism. No dose adjustment is recommended for patients with mild or moderate hepatic impairment. Care is recommended when using lutetium Lu 177 dotatate in patients with severe hepatic impairment (total bilirubin > 3 times upper limit of normal and any AST) as its safety has not been studied in these patients. Monitor transaminases, bilirubin and serum albumin during treatment.

References

  1. "Product Information. Lutathera (lutetium Lu 177 dotatate)." Advanced Accelerator Applications (2022):
Moderate

Lutetium Lu 177 dotatate (applies to lutetium lu 177 dotatate) myelosuppression

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Immunodeficiency, Bone Marrow Depression/Low Blood Counts

The use of lutetium Lu 177 dotatate may increase the risk of developing myelosuppression. Care should be exercised when using this agent in immunocompromised patients. It is recommended to monitor blood cell counts. Withhold, reduce dose, or permanently discontinue based on severity of adverse reaction.

References

  1. "Product Information. Lutathera (lutetium Lu 177 dotatate)." Advanced Accelerator Applications (2022):
Moderate

Lutetium Lu 177 dotatate (applies to lutetium lu 177 dotatate) renal dysfunction

Moderate Potential Hazard, Moderate plausibility.

Lutetium Lu 177 dotatate predominantly undergoes renal excretion. No dose adjustment is recommended for patients with mild to moderate renal impairment. It is recommended to assess renal function frequently in patients with mild to moderate impairment during therapy with this agent. . Monitor serum creatinine and calculated creatinine clearance. The safety of lutetium Lu 177 dotatate in patients with severe renal impairment or end-stage renal disease has not been studied

References

  1. "Product Information. Lutathera (lutetium Lu 177 dotatate)." Advanced Accelerator Applications (2022):

Lutetium lu 177 dotatate drug interactions

There are 227 drug interactions with lutetium lu 177 dotatate.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer